Risk for Postmarket Black Box Warnings in FDA-Approved Monoclonal Antibodies

OBJECTIVE: To estimate the potential risk for a future postmarket black box warning (BBW) of US Food and Drug Administration (FDA)-approved monoclonal antibodies (mAbs) because of the importance for medical clinicians to understand mAb risks and benefits, including unknown future risks, especially f...

Descripción completa

Detalles Bibliográficos
Autores principales: Hagan, John B., Ender, Elizabeth, Divekar, Rohit D., Pongdee, Thanai, Rank, Matthew A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724853/
https://www.ncbi.nlm.nih.gov/pubmed/35024565
http://dx.doi.org/10.1016/j.mayocpiqo.2021.11.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8724853/
https://www.ncbi.nlm.nih.gov/pubmed/35024565
http://dx.doi.org/10.1016/j.mayocpiqo.2021.11.009

Ejemplares similares